FTIR and MS Evidence for Heavy Metal Binding to Anti-amyloidal NAP-Like Peptides
- 108 Downloads
The octapeptide NAP (NAPVSIPQ) is a small sequence from the activity-dependent neuroprotective protein (ADNP), which is able to provide neuroprotection against Aβ toxicity even at low concentration. NAP provides protection against oxidative stress to brain cells and stimulates neurite outgrowth providing a neurotrophic and neuroprotective function. Therefore, we have investigated copper and silver binding to two NAP-like peptides, since our previous research revealed unexpected iron binding to such peptides. Here, we report on Cu(I) and Ag(I) binding to NAP and its Cys5 mutant. Our results revealed that NAP bind up to two silver ions but only one of copper as shown by Fourier transform infrared (FTIR) spectroscopy and MALDI-ToF mass spectrometry (MS). Surprisingly, its Cys5 mutant can bind four silver ions or three of copper, despite the fact that it is a small peptide molecule. The results were discussed in the view of NAP protection against Aβ induced neurotoxicity associated with Alzheimer disease (AD) and the relationship between Aβ peptides and heavy metal ions.
KeywordsNAP peptide FTIR MALDI-ToF MS Copper binding Silver binding Alzheimer disease
Funding from the Romanian Government (UEFISCDI Bucharest, PN-III-P4-ID-PCE-2016-0376; Contract 56 of 12.06.2017) is gratefully acknowledged. B.A. Petre acknowledges the PN-II-RU-TE-2014-4-0920 project for MS experiments.
- Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE (2000) A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann N Y Acad Sci 921:115–118. https://doi.org/10.1111/j.1749-6632.2000.tb06957.x CrossRefGoogle Scholar
- Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, Dyck CH, Thal L (2006) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11:353–368. https://doi.org/10.1111/j.1527-3458.2005.tb00053.x CrossRefGoogle Scholar
- Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609–7616. https://doi.org/10.1021/bi990438f CrossRefGoogle Scholar
- Ivanov AR, Nazimova IV, Baratova L (2000) Determination of biologically active low-molecular-mass thiols in human blood: I. Fast qualitative and quantitative, gradient and isocratic reversed-phase high-performance liquid chromatography with photometric and fluorescence detection. J Chromatogr A 895(2):157–166. https://doi.org/10.1016/S0021-9673(00)00713-5 CrossRefGoogle Scholar
- Jacobsen DW (1998) Homocysteine and vitamins in cardiovascular disease. Clin Chem 44:1833–1843Google Scholar
- Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li Q-X, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685–1691. https://doi.org/10.1001/archneur.60.12.1685 CrossRefGoogle Scholar
- Vellas B, Sol O, Snyder PJ, Ousset P-J, Haddad R, Maurin M, Lemarié J-C, Désiré L, Pando MP (2011) EHT0202/002 study group, EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 8:203–212. https://doi.org/10.2174/156720511795256053 CrossRefGoogle Scholar
- Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci USA 100:8543–8548. https://doi.org/10.1073/pnas.1331636100 CrossRefGoogle Scholar